Shares of Novavax jumped as much as 50% on Monday as Wall Street cheered the company's new multibillion- dollar deal with French drugmaker Sanofi that sparked a dramatic turnaround for the struggling vaccine maker. Novavax's stock almost doubled on Friday after it announced the licensing agreement with Sanofi. Novavax on Friday said the deal allows the company to remove its "going concern" warning, which it first issued in February 2023 due to major doubts about its ability to stay afloat. "It really does h ...

The 2020 U.S. equity crash and subsequent rebound was the perfect storm for a unique event called the "Meme" stock craze. After the panic lows of March 2020, stocks bottomed, and the government started to pump liquidity into the market and everyday Americans with stimulus checks. With many people working remotely, confined to their homes, and with more money in their pockets, Americans started trading in the stock market. By 2021, a message board called "Wallstreetbets" gained a cult-like following on the s ...

Luis Alvarez Novavax (NASDAQ:NVAX) has just announced mixed Q1 2024 earnings with a beat on EPS and a miss on revenue. NVAX surged by around 175% in premarket trading as investors applauded that their net loss narrowed by around 50% year-over-year to $148M, thanks to a 16% increase in revenue. In addition, investors were relieved to see the removal of the company’s going concern notice in the 10-Q, which was one of the geneses of the ticker’s relentless sell-off. However, I believe the primary cause of ...

A cloud of doubt hanging over the company just gave way to some sunshine.Shares of Novavax (NVAX 96.20%) are up 12% as of midday Friday following the release of the drugmaker's first-quarter results. It's not the report, however, driving the bulk of today's oversize gain -- it's the announcement made in conjunction with it.The company is partnering with fellow pharmaceutical company Sanofi (SNY 0.90%) to market Novavax's COVID vaccine. The deal also opens the door to the development of a flu vaccine based o ...

Novavax (NASDAQ:NVAX) stock investors are celebrating on Friday as the vaccine company’s shares hit a new 52-week high after announcing a deal with Sanofi (NASDAQ:SNY).This saw shares of NVAX stock climb as high as $9.22 per share during normal trading hours on Friday. That comes with some 142 million shares of the stock changing hands. For the record, this is well above its daily average of about 6.8 million shares.Investors will note that NVAX stock hasn’t been in this range since September 2022. However, ...

Novavax (NASDAQ:NVAX) stock has more than doubled today and is up more than 120% at the time of this writing. This morning, the company announced a co-exclusive licensing agreement with Sanofi (NASDAQ:SNY) to commercialize its Covid-19 vaccine. The agreement will also provide Sanofi with a sole license to the vaccine for use in combination with its flu vaccines.On top of that, Sanofi will receive “a non-exclusive license to use Novavax’s adjuvanted COVID-19 vaccine for use in combination with non-flu vaccin ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Key TakeawaysNovavax shares more than doubled in intraday trading Friday as it announced a $1.2 billion deal to license its vaccine technology to Sanofi.Novavax will co-commercialize its COVID-19 vaccine with the French drugmaker, along with developing others like a combination COVID-19 and flu vaccine.The vaccine maker also announced first-quarter results that included a wider-than-expected net loss. Novavax (NVAX) shares more than doubled in intraday trading Friday after announcing a $1.2 billion deal to ...

Forbes Community GuidelinesOur community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space.In order to do so, please follow the posting rules in our site's Terms of Service.  We've summarized some of those key rules below. Simply put, keep it civil.Your post will be rejected if we notice that it seems to contain:False or intentionally out-of-context or misleading informationSpamInsults, profanity, incoh ...

Exhibit 99.1 Press Release Novavax Reports First Quarter 2024 Financial Results and Operational Highlights GAITHERSBURG, Md., May 10, 2024 – Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced its financial results and operational highlights for the first quarter ended March 31, 2024. Earlier today, Novavax and Sanofi (NASDAQ: SNY) announced that they have entered into a co-exclusive licensing agreement. The terms of the agreement incl ...